PMID- 35677821
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Overview of Three Proliferation Pathways (Wnt, Notch, and Hippo) in Intestine and 
      Immune System and Their Role in Inflammatory Bowel Diseases (IBDs).
PG  - 865131
LID - 10.3389/fmed.2022.865131 [doi]
LID - 865131
AB  - Inflammatory bowel disease (IBD) is a disorder, which involves the 
      gastrointestinal (GI) tract consisting Crohn's disease (CD) and ulcerative 
      colitis (UC). The etiology of this disease is not yet clear and, hence, there are 
      numerous medications and treatments for patients with IBD, although a definite 
      and permanent treatment is still missing. Therefore, finding novel therapeutic 
      approaches are vital for curing patients with IBD. In the GI tract, there are 
      various lineages of cells with different roles that their existence is necessary 
      for the barrier function of intestinal epithelial cells (IECs). Therefore, 
      signaling pathways, which manage the hemostasis of cell lineages in intestine, 
      such as Wnt, Notch, and Hippo, could have crucial roles in regulation of barrier 
      function in the intestine. Additionally, these signaling pathways function as a 
      governor of cell growth, tissue homeostasis, and organ size. In patients with 
      IBD, recent studies have revealed that these signaling pathways are dysregulated 
      that it could result in depletion or excess of a cell lineage in the intestine. 
      Moreover, dysregulation of these signaling pathways in different cell lineages of 
      the immune system could lead to dysregulation of the immune system's responses in 
      IBD. In this article, we summarized the components and signaling of Wnt, Notch, 
      and Hippo pathways and their role in the intestine and immune system. 
      Furthermore, we reviewed latest scientific literature on the crosstalk among 
      these three signaling pathways in IBD. An overview of these three signaling 
      pathways and their interactions in IBD could provide a novel insight for 
      prospective study directions into finding efficient medications or treatments.
CI  - Copyright (c) 2022 Khoramjoo, Kazemifard, Baradaran Ghavami, Farmani, Shahrokh, 
      Asadzadeh Aghdaei, Sherkat and Zali.
FAU - Khoramjoo, Seyed Mobin
AU  - Khoramjoo SM
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Kazemifard, Nesa
AU  - Kazemifard N
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Baradaran Ghavami, Shaghayegh
AU  - Baradaran Ghavami S
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Farmani, Maryam
AU  - Farmani M
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Shahrokh, Shabnam
AU  - Shahrokh S
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Asadzadeh Aghdaei, Hamid
AU  - Asadzadeh Aghdaei H
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Sherkat, Ghazal
AU  - Sherkat G
AD  - Faculty of Mashhad Branch, Islamic Azad University, Mashhad, Iran.
FAU - Zali, Mohammad Reza
AU  - Zali MR
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220523
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9170180
OTO - NOTNLM
OT  - Hippo signaling
OT  - Notch signaling
OT  - Wnt signaling
OT  - immune system
OT  - inflammatory bowel disease
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/10 06:00
MHDA- 2022/06/10 06:01
PMCR- 2022/05/23
CRDT- 2022/06/09 02:23
PHST- 2022/01/29 00:00 [received]
PHST- 2022/04/14 00:00 [accepted]
PHST- 2022/06/09 02:23 [entrez]
PHST- 2022/06/10 06:00 [pubmed]
PHST- 2022/06/10 06:01 [medline]
PHST- 2022/05/23 00:00 [pmc-release]
AID - 10.3389/fmed.2022.865131 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 May 23;9:865131. doi: 10.3389/fmed.2022.865131. 
      eCollection 2022.